Physician profile
Ramsey K Umar
NPI 1134202500
$7,380.21
in general payments reported to CMS, 2019-2025
35 companies · $1,384 in 2025
The $1,384 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $467 · 2021: $1,252 · 2022: $1,271 · 2023: $1,454 · 2024: $1,297 · 2025: $1,384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,134.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,643.19 | 2019-2025 | Rinvoq, Mavyret, Linzess |
| Gilead Sciences, INC. | $1,004.04 | 2019-2025 | |
| Pfizer INC. | $448.91 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $411.60 | 2019-2025 | Entyvio |
| Ipsen Biopharmaceuticals, INC | $306.63 | 2024-2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.09 | 2019-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $250.83 | 2021-2025 | Stelara, Tremfya |
| Celgene Corporation | $242.97 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $194.33 | 2020-2023 | Rebyota |
| Phathom Pharmaceuticals, INC. | $177.90 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $162.37 | 2021-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $145.63 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $139.44 | 2019-2024 | Linzess |
| Regeneron Healthcare Solutions, INC. | $131.66 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $106.71 | 2022-2025 | Ibsrela |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $104.28 | 2025 | |
| Intercept Pharmaceuticals, INC. | $79.15 | 2020-2023 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $75.29 | 2021 | |
| Qol Medical, LLC | $72.47 | 2021-2025 | Sucraid, Sucraid |
| Organon LLC | $48.84 | 2022-2024 | |
| Biocon Biologics INC | $42.37 | 2025 | Yesintek |
| Amgen INC. | $37.71 | 2021 | |
| Capsovision, INC. | $35.59 | 2024 | Capsocam Plus |
| Lilly USA, LLC | $34.85 | 2024-2025 | Omvoh |
| Medtronic, INC. | $33.06 | 2022-2024 | Interstim |
| Shionogi INC | $27.82 | 2019 | |
| Abbott Laboratories | $27.06 | 2024 | Proclaim |
| Laborie Medical Technologies Corp. | $24.56 | 2024 | Solar Uroflow System |
| Orphalan INC | $22.06 | 2025 | Cuvrior |
| Pentax of America, INC. | $16.44 | 2022 | |
| Allergan, INC. | $15.41 | 2020 | |
| Madrigal Pharmaceuticals | $14.12 | 2025 | Rezdiffra |
| Ucb, INC. | $11.61 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.22 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$52,173.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramsey Umar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.